Drugs / VGM-R02b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06217861 | Apr 2024 → Aug 2027 expected | glutaryl-CoA dehydrogenase deficiency | Shanghai Vitalgen BioPharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGM-R02b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06217861 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “VGM-R02b is an adeno-associated viral vector 9 delivering human Glutaryl-CoA Dehydrogenase (GCDH) gene.” NCT06217861 ↗ |
| Route | Other | “intra-cerebroventricular injection could also be used for drug administration” NCT06217861 ↗ |